Lisata Slashes 72% of Workforce, Sues Kuva Labs After Failed Merger
LSTA is trading near its 52-week low of $0.988 (1.3% above the low) on elevated volume (1.9× avg).
Summary
Lisata Therapeutics is cutting 72% of its workforce effective immediately, a drastic move that signals the company is in survival mode after the collapse of its merger with Kuva Labs. The layoffs will cost an estimated $1.2 million through September 30, 2026. The company also terminated its Chief Medical Officer, Kristen K. Buck, and eliminated the Executive Vice President of R&D position. Certain separated staff may be engaged as external consultants for a period of time as necessary. Lisata has filed a lawsuit against Kuva Labs for breach of the merger agreement. This follows a series of setbacks: a going concern warning in May, repeated delays and amendments to the Kuva deal, and the ultimate termination of the merger in late July after Kuva failed to fund the tender offer. With a market cap under $10 million and shares trading near all-time lows, the company is now fighting for its existence. The lawsuit against Kuva is a critical wildcard—any recovery could provide a lifeline, but the near-term focus will be on whether Lisata can preserve enough cash to continue operations.
At the time of this announcement, LSTA was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.99 to $5.07. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.